Collectively, these findings highlight SKAP2 as a promising nonhormonal therapeutic target for correcting cytoskeletal defects in late-stage sperm development and suggest that EV-based protein delivery may represent a novel strategy for treating certain forms of male infertility. This evidence concerns the gene SKAP2 and male infertility.